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Abstract Several lines of evidence have been accumulating
indicating that an important role may be played by mitochondrial
homeostasis in the initiation phase, the first stage of apoptosis.
This work describes the results obtained by using different
inhibitors of monoamine oxidases (MAO), i.e. pargyline,
clorgyline and deprenyl, on mitochondrial integrity and apopto-
sis. Both pargyline and clorgyline are capable of protecting cells
from apoptosis induced by serum starvation while deprenyl is
ineffective. These data represent the first demonstration that
MAO-A inhibitors may protect cells from apoptosis through a
mechanism involving the maintenance of mitochondrial homeo-
stasis.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Apoptotic cell death is well known to be characterized by
several subcellular alterations leading to a speci¢c cell death
program [1]. Three steps can be distinguished: the initiation,
e¡ector and degradation phases. In the ¢rst phase, the cell
receives the death stimulus which may be represented by exog-
enous physical, chemical or biological agents or by a lack of
intracellular survival factors. In the subsequent e¡ector phase
several reactions can lead to cell death triggering. This regu-
latory step is followed by the degradation phase which is
irreversible and characterized by typical morphological and
histochemical markers of apoptosis including DNA fragmen-
tation [2]. It has recently been hypothesized that mitochon-
drial membrane potential [v8m] may play a key role in the
early events of the apoptotic cascade [3]. Thus, regulatory
mechanisms underlying mitochondrial activity in the cell
death program are currently under investigation in several
laboratories. Some endogenous and exogenous compounds
which could exert a proapoptotic or antiapoptotic regulatory
role, in£uencing mitochondrial homeostasis, have been
studied [3^5]. The presence of monoamine oxidase (MAO)
on the outer mitochondrial membrane can generate cytotoxic
species involved in the alteration processes of subcellular
structures. For instance, the damage of mitochondrial DNA
due to hydrogen peroxide, produced by oxidative deamination
of tyramine by FAD-dependent monoamine oxidase, has been
examined [6]. In light of this, we investigated the activity of
inhibitors of di¡erent MAO isoforms (A and B) on either the
mitochondrial membrane potential or apoptosis. Analytical
cytology analyses revealed that maintenance of the mitochon-
drial homeostasis by pargyline and clorgyline is associated
with a partial hindering of the apoptotic process.
2. Materials and methods
2.1. Cell cultures
Human melanoma cells (M14) were grown in monolayer in modi-
¢ed RPMI 1640 medium supplemented with 10% heat-inactivated
fetal calf serum (FCS), 1 mM sodium pyruvate, 1% non-essential
amino acids, 5 mM L-glutamine, penicillin (100 U/ml) and streptomy-
cin (100 Wg/ml) in an incubator at 37‡C containing a 95% air/5% CO2
atmosphere.
2.2. Withdrawal of growth factors (serum starvation) and treatments
with MAO inhibitors
35U104 cells/ml were plated in the medium supplemented with 10%
FCS. After 24 h the medium was replaced with RPMI 1640 without
serum, or containing 1% or 10% FCS in the presence of di¡erent
concentrations (1033 ; 1035 ; 1037 and 1039 M) of the following drugs.
(a) Pargyline (Sigma-Aldrich, N-benzyl-N-methyl propargylamine, Ki
15.3 WM for MAO-A and 1.8 WM for MAO-B). High concentrations
of pargyline inhibit both MAO isoforms while low concentrations
inhibit only MAO-B [7]. (b) Clorgyline (Sigma-Aldrich, N-methyl-N-
propargyl-3-(2,4-dichlorophenoxy)-propylamine). This compound is a
speci¢c MAO-A inhibitor. (c) Deprenyl (ICN Biomedicals, (R)-N,K-
dimethyl-N-2-propynylbenzeneethaneamine hydrochloride). This com-
pound is a speci¢c inhibitor of MAO-B. Over the course of 48 h
experiments these drugs were administered twice (time O and 24 h).
After 24 and 48 h at 37‡C, cells were collected for apoptosis evalua-
tion and measurement of mitochondrial membrane potential and
MAO activity.
2.3. Apoptosis evaluation
In order to determine apoptosis, the chromatin dye Hoechst 33258
(Molecular Probes, Eugene, OR, USA) was used to evaluate DNA
fragmentation as previously described [8]. The samples were observed
with a Nikon Microphot £uorescence microscope and quantitative
evaluation of apoptotic cells was performed by counting at least 300
cells at 500U magni¢cation.
2.4. Mitochondrial membrane potential
Cossarizza and coworkers have recently set up a new assay for
measuring mitochondrial membrane potential (v8m) and to study
apoptosis [9]. The method uses the lipophilic cationic probe
5,5P,6,6P-tetrachloro-1,1P,3,3P-tetraethyl-benzimidazolcarbocyanine io-
dide (JC-1, Molecular Probes). This probe, a monomeric molecule
emitting at 527 nm after excitation at 490 nm, is capable of selectively
entering the mitochondria. However, JC-1 is able to form aggregates
associated with a large shift in emission (590 nm) depending on the
v8m. Cell suspension was adjusted to a density of 0.5U106 cells/ml,
kept in the dark for 10 min at room temperature in medium contain-
ing 10% FCS and 10 Wg/ml JC-1 probe. JC-1 was dissolved and stored
according to the manufacturer’s instructions. After treatment, cells
were washed twice with PBS by centrifugation (1000Ug, 5 min) and
then resuspended in 400 Wl PBS. Samples containing no fewer than
2U105 cells were analyzed by FACScan £ow cytometer (Becton Dick-
inson, San JoseŁ, USA) equipped with a single 488 nm argon laser.
FEBS 20082 9-4-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 3 1 5 - 9
*Corresponding author. Fax. (39) (6) 49387140.
E-mail: Malorni@mclink.it
FEBS 20082 FEBS Letters 426 (1998) 155^159
Data were collected in list mode and analyzed using Lysys II software
(Becton Dickinson). Mitochondrial v8 alterations were analyzed in
cells undergoing apoptosis and in cells treated with MAO inhibitors as
described above.
2.5. Flow cytometry measurements
The ¢lter in front of the FL1 photomultiplier (PMT) has a band-
width of 30 nm and transmits at 530 nm, while the ¢lter used in the
FL2 channel has a bandwidth of 42 nm and transmits at 585 nm. For
the analysis of cells stained with JC-1, the PMT value of the FL1
detector was set at 360 V, and FL2 PMT at 300 V; FL1-FL2 and
FL2-FL1 compensation were 5.0% and 10.0% respectively.
2.6. MAO activity assay
After treatment with di¡erent drugs, cells were collected and
washed three times by centrifugation (1000Ug, 5 min) with PBS.
The cells were resuspended in PBS to the appropriate concentration
(50U106 cells/ml) and MAO-A and -B activity was assayed £uori-
metrically using kynuramine as substrate in the presence or absence
of various inhibitors. The activity was determined by measuring 4-
hydroxyquinoline (4HQ) and expressed per mg of protein during 30
min of incubation, at Vexc 315 nm and Vem 390 nm [10]. Endocellular
substrates of MAO, serotonin and dopamine, were detected by HPLC
method, according to MateŁs et al. [11].
2.7. Statistical analysis
The values reported in the ¢gures are the means þ standard devia-
tion (S.D.) from three separate experiments. Statistical analyses were
performed using Student’s t-test. A P value lower than 0.05 was con-
sidered signi¢cant.
3. Results
3.1. Apoptotic evaluation
Two di¡erent experimental conditions were considered:
M14 cells maintained in culture medium containing a low
amount of serum (1%) and M14 cells in medium deprived
of FCS. M14 cells grown in RPMI 1640 supplemented with
10% FCS were used as controls. In these conditions, after 24
h, the levels of apoptosis in control cells, detected as described
in Section 2, were very low (6 10%). As expected, some iso-
lated apoptotic cells along with numerous mitotic ¢gures were
found (not shown). By contrast (Fig. 1), after serum starva-
tion, the apoptosis rate was signi¢cantly higher and high par-
gyline concentrations (1 mM), capable of inhibiting both
MAO-A and MAO-B activity, were able to signi¢cantly re-
duce these values. In particular, after 48 h starvation a re-
markable apoptotic induction was detected: partial or com-
plete serum starvation led in the supernatants to the apoptosis
rates shown in Fig. 1 (mean values were 28% and 57% respec-
tively). Treatments with pargyline were able to partially pre-
vent this process by about 50% in both experimental condi-
tions (P6 0.01). Fig. 1b,c shows the morphological features of
apoptotic cells after 48 h starvation (b) and after pargyline
administration to starved cultures (c). A quantitative evalua-
tion of detached cells £owing freely in the supernatants also
indicated that the presence of pargyline in the medium was
capable of partially impairing cell detachment from the sub-
strate. In particular, a signi¢cant decrease in the number of
cells in the supernatants was observed in the presence of par-
gyline (44.2 þ 8% after 48 h serum starvation, 21.6 þ 5% in
pargyline treated samples, P6 0.05). Moreover, the above re-
sults were also con¢rmed by MAO activity in the cells. In fact,
the cells incubated for 48 h in the absence of serum showed an
inhibition of about 80% of the MAO activity in the presence
of 1 mM pargyline (4HQ values from 50 pmol/mg protein
normally detectable in starved cells decreased to 8.8 pmol/
mg protein in 1033 M pargyline treated cells). The inhibitory
e¡ect on MAO activity was also con¢rmed by an increase of
serotonin (0.59^4.41 nmol/106 cells) and dopamine (0.012^
0.24 nmol/106 cells). Further analyses of apoptotic cells were
also conducted by using lower pargyline concentrations in an
attempt to inhibit only the MAO-B enzyme. Results are sum-
marized in Fig. 2 and indicate that lower pargyline concen-
trations (1035 and 1037 M) correspond to lower protection
from apoptosis. The lowest dose used (1039 M) was com-
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Fig. 1. Apoptosis rate after 24 and 48 h of cell treatment with par-
gyline. Two di¡erent experimental conditions were considered: M14
cells maintained with low levels of serum (1%) and M14 cells com-
pletely deprived of FCS. M14 cells growing in 10% FCS supple-
mented medium were used as controls. b,c: Morphological features
of apoptotic cells after 48 h starvation (b) and after pargyline ad-
ministration to starved cultures (c). Arrows indicate chromatin con-
densation and/or clumping typical of apoptosis.
Fig. 2. Apoptosis rates in M14 cells grown in serum-deprived me-
dium and treated with di¡erent concentrations of the MAO inhibi-
tors pargyline, clorgyline or deprenyl for 48 h. The apoptotic phe-
nomenon is signi¢cantly decreased only by administration of
pargyline and clorgyline.
W. Malorni et al./FEBS Letters 426 (1998) 155^159156
pletely ine¡ective (Fig. 2) and 4HQ values were at least double
those reported above for pargyline 1 mM (e.g. 16 pmol/mg
protein in 1037 M pargyline treated samples). In addition,
parallel experiments carried out by using speci¢c inhibitors
of MAO-A (clorgyline) and MAO-B (deprenyl) were also per-
formed. According to the above results, a concentration-de-
pendent protection was found after clorgyline administration
while deprenyl was ine¡ective at all concentrations used (Fig.
2). In particular, high concentrations of clorgyline (1033 M)
were toxic to M14 cells (cell loss s 80%) while low concen-
trations (1035^1037 M, Fig. 2) were capable of producing a
signi¢cant decrease of the apoptotic cell rate. Accordingly,
4HQ concentrations were very low (about 7 pmol/mg pro-
tein). By contrast, no statistically signi¢cant e¡ects were found
after deprenyl treatments either in the apoptotic values or in
the 4HQ concentrations, which were similar to those of
starved cells, 41 pmol/mg protein.
3.2. Mitochondrial membrane potential evaluation
Cell loading with JC-1 was then performed in order to
obtain information about v8m in both control and treated
cells. Cyto£uorimetric studies allowed us to detect that v8m
was a¡ected by serum deprivation in a time dependent man-
ner as shown in Fig. 3. After 48 h starvation M14 cells
showed a marked increase in mitochondrial membrane depo-
larization. This is represented by the alterations of the contour
plot as shown in Fig. 3k. In fact, according to the above
method [8], the cells with depolarized mitochondria are those
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Fig. 3. Mitochondrial membrane potential (v8m). Left panel (a^d): 10% FCS-supplemented cells (controls); central panel (e^h): 1% FCS-sup-
plemented cells; right panel (i^l) : starved cultured cells. Abscissa: FL1 (green £uorescence, log scale); ordinate: FL2 (orange £uorescence, log
scale). CTR: pargyline untreated cells ; PGR: pargyline treated. A representative experiment of three is shown.
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moving from the middle of the quadrant to the lower right
corner, as they lose greenish orange £uorescence (in FL2).
This e¡ect was consistently reduced by the presence of pargy-
line in the medium (Fig. 3l). In Fig. 4a a quantitative evalua-
tion of these changes is shown. A high percentage of cells with
depolarized mitochondria is detectable after serum depriva-
tion, while the number of cells with compromised mitochon-
dria showed a signi¢cant decrease after pargyline administra-
tion (P6 0.01). The same analyses have also been carried out
by analyzing mitochondrial membrane potential after treat-
ment with various concentrations of MAO inhibitors. The
results obtained indicate that, according to the above reported
results on apoptosis (Fig. 2), both pargyline and clorgyline,
but not deprenyl, are capable of protecting the cells against
mitochondrial damage. In fact, £ow cytometry analyses indi-
cated that signi¢cant protection is o¡ered by these drugs after
both partial (1%) and complete starvation protocols (not
shown). The quantitative evaluation of these data is shown
in Fig. 4b and indicates signi¢cant protection exerted only by
drugs acting on MAO-A, i.e. high pargyline concentrations
and clorgyline.
4. Discussion
The importance of mitochondrial activity in the ¢rst phase
of apoptotic triggering was ¢rst pointed out in 1993 [5]. In
particular, mitochondrial membrane potential was investi-
gated in order to determine whether any alteration of this
important function could be related to the cascade of events
occurring intracellularly during apoptosis [2]. Di¡erent ap-
proaches have been considered, including structural and bio-
physical ones [12,13]. However, e¡orts made by Kroemer’s
group using a plethora of di¡erent £uorescent probes dis-
closed the possibility of approaching the study of mitochon-
drial activity in the course of apoptosis by £ow cytometry [3].
Our group also contributed to these e¡orts by proposing the
use of a speci¢c probe, JC-1, which is endowed with a mito-
chondrial targeted compound for analyzing alterations of mi-
tochondrial membrane potential [9,14,15]. The present work
describes one early event in the induction of apoptosis, which
may be represented by the alteration of mitochondrial integ-
rity and its homeostasis. Pargyline and clorgyline were able to
prevent this process through a mechanism involving the main-
tenance of mitochondrial homeostasis. This may be related to
the previously suggested activity of the drugs on ion regula-
tion [16] as well as to a decreased production of reactive oxy-
gen species. MAOs, as reported above, catalyze the oxidative
deamination of biogenic amines producing aldehydes and
H2O2 which, in turn, are key molecules in apoptotic induction
mechanisms [17]. MAO inhibition is in fact associated with a
decrease in production of both oxygen radicals and aldehydes
during the catalytic cycle representing a risk for mitochondrial
integrity [6]. For instance, it has been shown that H2O2 and
aldehydes produced during the enzymatic oxidation of exog-
enous spermine by puri¢ed bovine serum amine oxidase have
been shown to cause cytotoxicity in cultured cells [18]. Fur-
ther, oxidation-dependent mechanisms of apoptosis after ex-
posure to spermidine have also been described [19].
Mitochondrial MAO-A and -B are irreversibly and specif-
ically inhibited by propargylamine (or acetylenic) derivatives
[20]. In particular, pargyline is capable of inhibiting both
MAO isoforms when used at high (millimolar) concentrations
[20]. In fact, in our experimental conditions, a powerful in-
hibitory e¡ect on both apoptosis and MAO activity was ex-
erted by high doses of pargyline. In contrast, with lower drug
concentrations (beyond 1037 M), mitochondrial membrane
potential and apoptotic cell death appeared to occur nor-
mally. In this context, the importance of other speci¢c
MAO inhibitors, such as clorgyline for MAO-A and deprenyl
for MAO-B, was considered. We found that only the former
was e¡ective in providing a signi¢cant protection from apop-
tosis and v8 changes. The absence of deprenyl protection
could be imputable to the low MAO-B content in the mela-
noma cells considered here. On the other hand, the non-linear
inhibition of MAO activity as a function of pargyline and
clorgyline concentrations could be partially explained by the
fact that these drugs are suicide inhibitors [21] and by the
observation that a non-speci¢c binding of MAO inhibitors
to sites other than MAO active sites has been proposed [22].
These data seem to imply that, at least in withdrawal of
growth factor-induced apoptosis, i.e. in protein synthesis-in-
dependent apoptosis, an important role may be played by
MAO-A-associated mitochondrial activity. In fact, a di¡erent
mechanism for protecting from apoptosis in pheochromocy-
toma cells (PC12) using deprenyl was reported [23]. Induction
of protein synthesis may explain the protective e¡ect of low
deprenyl concentrations (1039^10311 M), which are not su⁄-
cient to inhibit MAO-A, the only isoform present in PC12
cells ; partial apoptosis protection in the same cells by pargy-
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Fig. 4. Percentage of M14 cells with depolarized mitochondria. a:
Deprivation of serum induced a marked increase in the number of
cells with mitochondrial depolarization. Pargyline treatment (1033
M) is able to signi¢cantly prevent (P6 0.01) mitochondrial damage.
b: Treatment with di¡erent concentrations of pargyline, clorgyline
or deprenyl. Only treatment with pargyline and clorgyline signi¢-
cantly (P6 0.01) prevents apoptosis-associated mitochondrial dam-
age, induced by starvation, in a dose-dependent manner. In con-
trast, deprenyl is ine¡ective at all doses used.
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line (1033^1037 M) was also observed [23]. Thus, in conclu-
sion, our work o¡ers the ¢rst evidence of a possible speci¢c
activity of MAO-A inhibitors in partially hindering the mito-
chondrially triggered cell death program and, more in general,
in the maintenance of mitochondrial homeostasis. Our con-
clusions are in agreement with the recent paper by Hu and
Pegg [24] on the apoptosis hindering exerted by polyamine
oxidase activity inhibitors. These authors suggest that pro-
grammed cell death can be caused by the oxidation products
of polyamines. In light of this, our data further address the
question strongly suggesting that the mitochondrial H2O2
and/or aldehyde in situ production can also play a major
role in triggering apoptosis.
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